The INTERCEPT study showed the potential of broader genetic testing to personalize treatment approaches for cancer patients.

Quidel expects to launch at least four new products over the next year and commented on its overall COVID-19 strategy, as well as R&D plans, M&A possibilities, and other updates.

Qiagen can now sell Phase's proprietary proximity-ligation technology for chromatin conformational analysis research in the US.

The startup has launched oncology and pulmonology beta tests at five US health systems, with help from precision health firm mProbe and several pharma partners.

Data presented at the ASHG virtual meeting highlighted the population insights that can be gleaned from IDB profiles in populations, including loci linked to blood traits.

The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.

The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.

A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.

In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.

News items for the week of Oct. 26, 2020. 

To support the 1+ Million Genomes Initiative, the EC has funded a new project, called Beyond 1 Million Genomes, with €4 million over the next three years.

Oxsed, a University of Oxford spinout, will continue to focus on prioritizing test access for low- and middle-income countries following the acquisition.

The point-of-care test runs on the VitaPCR instrument and delivers results in 20 minutes, and has been implemented at Charles De Gaulle airport.

The reissued EUA is for the qualitative detection of nucleic acid from SARS-CoV-2 in human oropharyngeal swab, nasopharyngeal swab, and anterior nasal swab specimens.

During a session at the ASHG 2020 virtual meeting, representatives from both organizations laid out the reasons for their contrasting guidelines.

The firm's subsidiary BioReference Laboratories performed 3.5 million COVID-19 PCR tests and 300,000 serology tests during the quarter.

DotLab, a women's health company developing a microRNA-based test for endometriosis, has formed its scientific advisory board. Appointees include Kristof Chwalisz, therapeutic area head urology, gynecology at Abbott Laboratories; Anula Jayasuriya, founder and managing director at EXXclaim Capital; Thomas Musci, former chief medical officer at Ariosa Diagnostics (acquired by Roche) and former faculty member at the University of California, San Francisco; Harold Sauer, chairman of the department of obstetrics and gynecology at Bridgeport Hospital, part of the Yale New Haven Health System; Eric Surrey, medical director at the Colorado Center for Reproductive Medicine; and Robert Taylor, professor of obstetrics and gynecology and assistant dean and director of the Md-PhD program at the University at Buffalo.

Oxford Nanopore Technologies has released a number of new and updated analysis tools and products. Bonito CRF, a new basecalling algorithm currently available for early users, improves modal raw-read accuracy to 98.3 percent on internal validation sets. The new SV Pipeline 2.0 increases structural variation calling precision to 97.5 percent and recall to 95.5 percent. The new DeepVariant tool, when paired with the existing Medaka tool, identifies SNPs with 99.92 percent recall and precision. The company also said it is commercially releasing the R10.3 flow cells for use with the high-throughput PromethIon sequencer and the low-throughput Flongle sequencing adapter.

Bio-Rad's year-over-year Q3 revenue increase was driven primary by sales of PCR and Droplet Digital PCR products due to the COVID-19 pandemic.

Illumina reported total third quarter revenues of $794 million. On the investor conference call, Illumina's CEO justified the $8 billion Grail deal.

The company reported $53.4 million in total revenues for the quarter and said testing services revenues rose 61 percent year over year.

The firm reported $57.8 million in revenues for its Lyra SARS-CoV-2 molecular diagnostic assays in the quarter.

The company said that at a time of unparalleled growth, it is building three new manufacturing lines and expanding resources for future assay development.